From April 15 to 17, 2026, Jilin Qijian Bio-pharmaceutical Co., Ltd. participated in EXPOFARMA 2026 in Mexico City, further expanding its presence in the Latin American pharmaceutical market.



During the exhibition, Qijian Bio engaged with industry professionals and business representatives across the pharmaceutical sector, and showcased its capabilities in Somatropin, Semaglutide, and GM-1 (Monosialotetrahexosylganglioside Sodium). The company also held in-depth discussions with customers and partners on API supply, formulation cooperation, registration support, and international market development.

Among the products presented, Somatropin API attracted particular attention. Qijian Bio’s manufacturing system, quality management, and international compliance experience were well recognized by visitors and potential partners. Through EXPOFARMA, the company further strengthened its brand presence in Latin America and created new opportunities for future cooperation.



Looking ahead, Qijian Bio will continue to advance its international development strategy, participate in global pharmaceutical exhibitions, and work with partners worldwide to support the development of the healthcare industry.